A Novel, Killed-Virus Nasal Vaccinia Virus Vaccine-Reference-Cited by-同舟云学术

A Novel, Killed-Virus Nasal Vaccinia Virus Vaccine

Published:2008-02 Issue:2 Volume:15 Page:348-358
ISSN:1556-6811
Container-title:Clinical and Vaccine Immunology
language:en
Short-container-title:Clin Vaccine Immunol

Author:

Bielinska Anna U.¹²,Chepurnov Alexander A.¹²,Landers Jeffrey J.¹²,Janczak Katarzyna W.¹²,Chepurnova Tatiana S.¹²,Luker Gary D.¹²,Baker James R.¹²

Affiliation:

1. Michigan Nanotechnology Institute for Medicine and Biological Sciences (MNIMBS), University of Michigan, Ann Arbor, Michigan 48109

2. Department of Radiology, University of Michigan, Ann Arbor, Michigan 48109

Abstract

ABSTRACT Live-virus vaccines for smallpox are effective but have risks that are no longer acceptable for routine use in populations at minimal risk of infection. We have developed a mucosal, killed-vaccinia virus (VV) vaccine based on antimicrobial nanoemulsion (NE) of soybean oil and detergent. Incubation of VV with 10% NE for at least 60 min causes the complete disruption and inactivation of VV. Simple mixtures of NE and VV (Western Reserve serotype) (VV/NE) applied to the nares of mice resulted in both systemic and mucosal anti-VV immunity, virus-neutralizing antibodies, and Th1-biased cellular responses. Nasal vaccination with VV/NE vaccine produced protection against lethal infection equal to vaccination by scarification, with 100% survival after challenge with 77 times the 50% lethal dose of live VV. However, animals protected with VV/NE immunization did after virus challenge have clinical symptoms more extensive than animals vaccinated by scarification. VV/NE-based vaccines are highly immunogenic and induce protective mucosal and systemic immunity without the need for an inflammatory adjuvant or infection with live virus.

Publisher

American Society for Microbiology

Subject

Microbiology (medical),Clinical Biochemistry,Immunology,Immunology and Allergy

Link

https://journals.asm.org/doi/pdf/10.1128/CVI.00440-07

Reference42 articles.

1. Blasco, R., and B. Moss. 1995. Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene158:157-162.

2. Bonilla-Guerrero, R., and G. A. Poland. 2003. Smallpox vaccines: current and future. J. Lab. Clin. Med.142:252-257.

3. Centers for Disease Control and Prevention. 2003. Multistate outbreak of monkeypox—Illinois, Indiana, Kansas, Missouri, Ohio and Wisconsin. MMWR Morb. Mortal. Wkly. Rep.52:642-646.

4. Couch, R. B. 2004. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N. Engl. J. Med.350:860-861.

5. Coulibaly, S., P. Bruhl, J. Mayrhofer, K. Schmid, M. Gerencer, and F. G. Falkner. 2005. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology341:91-101.

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoemulsions: Summary of a Decade of Research and Recent Advances;Nanomedicine;2024-01-31

2. A Glance on Nanovaccine: A Potential Approach for Disease Prevention;Current Pharmaceutical Biotechnology;2023-10-11

3. Progress and prospects on vaccine development against monkeypox infection;Microbial Pathogenesis;2023-07

4. Smallpox and Vaccinia;Plotkin's Vaccines;2023

5. Development of a Purified Viral Preparation for Studies of COVID-19 (SARS-CoV-2) Biology;Bulletin of Experimental Biology and Medicine;2021-11